Skip to content

Geron GERN Enterprise value

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Incyte logo
IncyteINCY
$15.31B+55.9%
Immunome logo
ImmunomeIMNM
$1.9B+470%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$2.28B+84.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2.62B+275%
Celcuity logo
CelcuityCELC
$5.51B+1,086%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-7.6%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Calculated from Geron’s reported figures.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's enterprise value?
Geron (GERN) reported enterprise value of $1.04B in Q1 2026.
How has Geron's enterprise value changed year-over-year?
Geron's enterprise value decreased by 3.6% year-over-year, from $1.08B to $1.04B.
What is the long-term trend for Geron's enterprise value?
Over 5 years (2020 to 2025), Geron's enterprise value has grown at a 11.4% compound annual growth rate (CAGR), from $531.69M to $910.69M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.